Shaomeng Wang

1986-1992 chemistry University of Michigan, Ann Arbor, Ann Arbor, MI 
Molecular Therapeutics
"Shaomeng Wang"

Dr. Wang received his B.S. in Chemistry from Peking University in 1986 and his Ph.D. in Chemistry from Case Western Reserve University in 1992. Dr. Wang did his postdoctoral training in drug design at the National Cancer Institute, NIH between1992-1996. Dr. Wang was Assistant Professor at Georgetown University from 1996-2000 and Associate Professor from 2000-2001. Dr. Wang joined the faculty at the University of Michigan Medical School as a tenured Associate Professor in 2001 and was promoted to Professor in 2006. Dr. Wang was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007. Dr. Wang serves as the Co-Director of the Molecular Therapeutics Program at the University of Michigan Comprehensive Cancer Center and is the Director of the Cancer Drug Discovery Program at the University of Michigan.

Mean distance: 9.25
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kregel S, Wang C, Han X, et al. (2020) Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia (New York, N.Y.). 22: 111-119
Zhou H, Lu J, Yang CY, et al. (2020) Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. Advances in Experimental Medicine and Biology. 1217: 349-362
Guo Z, Liu H, Zhou H, et al. (2019) High-order acoustic vortex field generation based on a metasurface. Physical Review. E. 100: 053315
Han X, Zhao L, Xiang W, et al. (2019) Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. Journal of Medicinal Chemistry
Lee SY, Kim H, Li CM, et al. (2019) Casein kinase-1γ1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3. Cell Death & Disease. 10: 923
Zhou H, Bai L, Xu R, et al. (2019) Structure-Based Discovery of SD-36 as a Potent, Selective and Efficacious PROTAC Degrader of STAT3 Protein. Journal of Medicinal Chemistry
Bai L, Zhou H, Xu R, et al. (2019) A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 36: 498-511.e17
Yang J, Li Y, Aguilar A, et al. (2019) Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. Journal of Medicinal Chemistry
Aguilar A, Zheng K, Xu T, et al. (2019) Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. Journal of Medicinal Chemistry
Yang CY, Qin C, Bai L, et al. (2019) Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Drug Discovery Today. Technologies. 31: 43-51
See more...